TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15104324

Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, IPPMG Hospital
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, IFF Hospital (Room 1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, IFF Hospital (Room 2)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, IFF Hospital (Mobile Equipment)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, Omdurman Hospital
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, Khartoum Hospital
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, Ahmed Gasim Hospital
Number of subjects: 5
Study: 11668667

Group type: EXPERIMENTAL
Intervention: 50 microg CCK-4 during REM sleep
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50 microg CCK-4 during delta sleep
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 microg CCK-4 during REM sleep
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 microg CCK-4 during delta sleep
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CCK-4 during delta sleep
Number of subjects: 15
Study: 9830891

Group type: EXPERIMENTAL
Intervention: Bow method
Number of subjects: 222

Group type: COMPARATOR
Intervention: Knot method
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 222
Study: 7862896

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg ethanol mixed into a drink of caffeine-free cola
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ethanol and stress combined
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ethanol and stress
Number of subjects: 44
Study: 2510266

Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms b.d.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 1102259

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Indomethacin 100 mg daily
Number of subjects: 23
Study: 31539025

Group type: EXPERIMENTAL
Intervention: Preoperative volume replacement therapy (VRT) - 1 ml/kg/h of Hartmann's solution for 12 hours
Number of subjects: 169

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Preoperative volume replacement therapy (VRT)
Number of subjects: 169
Study: 31398361

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 15 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study: 28484817

Group type: EXPERIMENTAL
Intervention: Pen Torch Transillumination (PTI)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Veinlite® EMS (TransLite®, Texas, USA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional venepuncture (control)
Number of subjects: 69
Study: 26380441

Group type: EXPERIMENTAL
Intervention: Xinmailong Injection (100 mg/2 mL, by dripping at 5 mg/kg, twice per day for 5 consecutive days)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Xinmailong Injection
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (XI mimetic agent, 100 mg/2 mL, by dripping at 5 mg/kg, twice per day for 5 consecutive days)
Number of subjects: 238
Study: 24377214

Group type: EXPERIMENTAL
Intervention: Three therapies of strong stimulation (strong pricking therapy, strong cupping therapy, strong moxibustion)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Half-needling technique combined with moxa stick therapy
Number of subjects: 80
Study: 22032936

Group type: EXPERIMENTAL
Intervention: Positive picture‐word cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative picture‐word cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mixed picture‐word cues (control)
Number of subjects: 0
Study: 19877110

Group type: EXPERIMENTAL
Intervention: Training program (basic training module)
Number of subjects: 2795

Group type: EXPERIMENTAL
Intervention: Training program (specific modules)
Number of subjects: 2795

Group type: EXPERIMENTAL
Intervention: Training program (overall)
Number of subjects: 2795
Study: 17023828

Group type: EXPERIMENTAL
Intervention: 30 minutes of moderate intensity exercise (intermittent run-walk on a treadmill at 70% to 85% of VO(2) peak)
Number of subjects: 10
Study: 12833465

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m² on Days 1 and 8) and Cisplatin (70 mg/m² on Day 2) for 4 cycles (GC)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin (GC)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Definitive adjuvant radiotherapy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy
Number of subjects: 129
Study: 10642233

Group type: EXPERIMENTAL
Intervention: Multifaceted educational programme for 2.5 hours a week over six weeks, followed by a two-hour session of case discussion and debriefing.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Multifaceted educational programme.
Number of subjects: 108
Study: 8878497

Group type: EXPERIMENTAL
Intervention: Routine colonoscopy and carcinoembryonic antigen evaluation every three months, with colonoscopy performed preoperatively, 12 to 15 months after surgical treatment, and then at intervals of 12 to 24 months or when symptoms appeared.
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Asymptomatic patients undergoing radical operation for recurrence.
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen evaluation as a marker for recurrence.
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Colonoscopy performed within the first 12 to 15 months after operation.
Number of subjects: 481
Study: 1387849

Group type: EXPERIMENTAL
Intervention: Growth hormone (12 IU/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 6395642

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 20
Study: 31197602

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy patients with LOC eating
Number of subjects: 145
Study: 30848697

Group type: EXPERIMENTAL
Intervention: del Nido Cardioplegia
Number of subjects: 56

Group type: COMPARATOR
Intervention: blood Cardioplegia
Number of subjects: 56
Study: 28437264

Group type: EXPERIMENTAL
Intervention: MgSO4 50 mg/kg intravenously for 10 min, followed by a continuous infusion of 15 mg/kg/h during surgery
Number of subjects: 66

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: MgSO4
Number of subjects: 66
Study: 26232277

Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 78

Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 78

Group type: COMPARATOR
Intervention: no-OAC
Number of subjects: 78
Study: 24105269

Group type: EXPERIMENTAL
Intervention: Communication tool in addition to the IPCRG sheet
Number of subjects: 114

Group type: COMPARATOR
Intervention: IPCRG sheet only
Number of subjects: 114
Study: 20833737

Group type: EXPERIMENTAL
Intervention: BILAG 2004 index
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SELENA flare instrument
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Physician's global assessment (PGA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BILAG 2004 flare
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SELENA flare
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PGA
Number of subjects: 16
Study: 18053002

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) administration at a dose of 0.4 g/kg daily for 6 months
Number of subjects: 39
Study: 17086029

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators (ICDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary and primary prevention trials with ICDs
Number of subjects: 0
Study: 12924170

Group type: EXPERIMENTAL
Intervention: One placebo tablet a day
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Two placebo tablets a day
Number of subjects: 197
Study: 10941692

Group type: EXPERIMENTAL
Intervention: Recruitment strategy for a primary prevention study testing aspirin
Number of subjects: 47453

Group type: EXPERIMENTAL
Intervention: Focus groups with 225 randomly selected 'eligible refusers'
Number of subjects: 47453
Study: 9470874

Group type: EXPERIMENTAL
Intervention: Björk‐Shiley convexo‐concave (BScc) valve
Number of subjects: 137

Group type: COMPARATOR
Intervention: Sorin Biomedical spherical valve
Number of subjects: 137
Study: 8331700

Group type: EXPERIMENTAL
Intervention: Recombinant human superoxide dismutase (rhSOD, 3000 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3553277

Group type: EXPERIMENTAL
Intervention: Albuterol powder (200 micrograms)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Albuterol aerosol (180 micrograms)
Number of subjects: 231
Study: 29803772

Group type: EXPERIMENTAL
Intervention: CuSum-guided curriculum
Number of subjects: 46

Group type: COMPARATOR
Intervention: Volume-based training arm
Number of subjects: 46
Study: 26129873

Group type: EXPERIMENTAL
Intervention: Preferred music
Number of subjects: 14

Group type: COMPARATOR
Intervention: Classical 'relaxation' music
Number of subjects: 14
Study: 24477186

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (Thymoglobulin)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 171

Group type: COMPARATOR
Intervention: Combined groups A and C (Antithymocyte globulin and Daclizumab)
Number of subjects: 171
Study: 24136691

Group type: EXPERIMENTAL
Intervention: Exercise heart rate monitors (HRMs) during guided mindfulness, diaphragmatic breathing, and progressive muscle relaxation techniques
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (techniques alone without HRM)
Number of subjects: 53
Study: 21388442

Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg once daily
Number of subjects: 379

Group type: COMPARATOR
Intervention: exenatide 10 μg twice daily
Number of subjects: 379
Study: 18513453

Group type: EXPERIMENTAL
Intervention: Amoxicillin (50 mg/kg/d BD)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 17151174

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 12702894

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 450

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 10896693

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I) immunoreactivity in skin of ALS patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Duration of illness in ALS patients
Number of subjects: 34
Study: 8941104

Group type: EXPERIMENTAL
Intervention: Carvedilol (n = 133; target dose, 25 to 50 mg BID)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo (n = 145)
Number of subjects: 278
Study: 1631473

Group type: EXPERIMENTAL
Intervention: Various medical and surgical treatments for endometriosis and medically assisted fertilization (IVF)
Number of subjects: 0
Study: 2877327

Group type: COMPARATOR
Intervention: Highly rigid fixation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Axial micromovement applied across the fracture site for 30 min per day
Number of subjects: 85
Study: 29954370

Group type: EXPERIMENTAL
Intervention: Motivational interviewing techniques educational session
Number of subjects: 2389

Group type: COMPARATOR
Intervention: Control group (no educational session)
Number of subjects: 2389
Study: 27604993

Group type: EXPERIMENTAL
Intervention: Nivolumab treatment
Number of subjects: 1
Study: 24100150

Group type: EXPERIMENTAL
Intervention: High-dose rate brachytherapy (HDR-BT) with 2 × 8.5 Gy after external beam radiotherapy (EBRT) of 35.75 Gy in 13 fractions
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: D₉₀ and V₁₀₀ at or above the second and third quartile
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Minimum D₉₀ of 108% of the prescribed dose
Number of subjects: 108
Study: 21899956

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no stress induction)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Stressed group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Females (in both groups)
Number of subjects: 65
Study: 16052573

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), 20-25 mg/week
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC), 2 mg/kg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 100
Study: 12483765

Group type: EXPERIMENTAL
Intervention: Methods based upon the variance ratio statistic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Searle's method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusted versions of Searle's method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thomas and Hultquist's method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence intervals for the methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from cluster based studies
Number of subjects: 0
Study: 10921043

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with interventional therapy (chemotherapeutic drugs, biological response modifiers, or Chinese medicinal herbs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 60
Study: 7857502

Group type: EXPERIMENTAL
Intervention: Hypericum extract LI 160 (3 x 300 mg daily)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Imipramine (3 x 25 mg daily)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both treatments (LI 160 and Imipramine)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: LI 160
Number of subjects: 135
Study: 2519687

Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bednets
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo-treated bednets
Number of subjects: 16
Study: 792359

Group type: EXPERIMENTAL
Intervention: Amikacin plus penicillin G (Amik-Pen)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Amikacin plus carbenicillin (Amik-Carb)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined antibiotics with demonstrated synergy in vitro
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined antibiotics without demonstrated synergy in vitro
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Peak serum antimicrobial dilution titer ≥ 1:8
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Peak serum antimicrobial dilution titer < 1:8
Number of subjects: 50
Study: 30098003

Group type: EXPERIMENTAL
Intervention: SMART (self-management for people with epilepsy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SMART
Number of subjects: 60

Group type: COMPARATOR
Intervention: WL (waitlist control)
Number of subjects: 60
Study: 25806400

Group type: EXPERIMENTAL
Intervention: 300 mcg spinal morphine and 1 gram acetaminophen every 6 hours for 24 hours postoperatively
Number of subjects: 74

Group type: COMPARATOR
Intervention: 150 mcg spinal morphine and placebo tablets
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 74
Study: 24937546

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (35,000 IU/wk)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 22398159

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20167176

Group type: EXPERIMENTAL
Intervention: Moderate exercise program (group A, n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intense exercise program (group B)
Number of subjects: 16
Study: 18382826

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the unaffected hemisphere (25 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 16088297

Group type: EXPERIMENTAL
Intervention: Balsamodendron mukul (1.5 g/d)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg/d)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combined therapy with Balsamodendron mukul (1.5 g/d) and nifedipine (10 mg/d)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control subjects (untreated hypertensive patients)
Number of subjects: 57
Study: 11861235

Group type: EXPERIMENTAL
Intervention: Infant formulas with reduced allergenicity
Number of subjects: 2252
Study: 10438693

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 75

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 75
Study: 7872385

Group type: EXPERIMENTAL
Intervention: Excimer laser photorefractive keratectomy using a multiple zone technique
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Retreatments performed on 4 patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitrogen gas blowing during treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity loss
Number of subjects: 12
Study: 2222103

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 151476

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control infusion with saline
Number of subjects: 23
Study: 31571243

Group type: EXPERIMENTAL
Intervention: Immediate periodontal therapy (test group, n=46)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Delayed periodontal therapy (control group, n=46)
Number of subjects: 92
Study: 31204146

Group type: EXPERIMENTAL
Intervention: Deep pressure input during third molar extraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no deep pressure input)
Number of subjects: 0
Study: 28930174

Group type: EXPERIMENTAL
Intervention: Capsaicin (4 mg daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (0.05 mg daily)
Number of subjects: 42
Study: 25369588

Group type: EXPERIMENTAL
Intervention: Multiparametric staining using CFSE and glycophorin A antibody
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Multiparametric staining using CFSE, glycophorin A antibody, and annexin V
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation between haemolysis rate (HR%) and number of microparticles detected
Number of subjects: 10
Study: 23836515

Group type: EXPERIMENTAL
Intervention: Cardiovascular training (3 units per week for 12 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Attention control (regular discussion groups on coping strategies)
Number of subjects: 106
Study: 21747355

Group type: EXPERIMENTAL
Intervention: Generic atorvastatin (GA)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Reference atorvastatin (RA)
Number of subjects: 148
Study: 20108741

Group type: EXPERIMENTAL
Intervention: commercial raisin bran cereal (cRB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: bran flakes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: raisins
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: experimental raisin bran cereal (eRB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 percent sucrose
Number of subjects: 20

Group type: COMPARATOR
Intervention: sorbitol
Number of subjects: 20
Study: 17124819

Group type: EXPERIMENTAL
Intervention: PVL film dressing
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 49
Study: 15465940

Group type: EXPERIMENTAL
Intervention: Telephone consultation by nurses and paramedics using a computerized decision support system
Number of subjects: 635
Study: 11704495

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 28
Study: 9129558

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg orally once a day for 4 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7939081

Group type: EXPERIMENTAL
Intervention: Sustained release formulation of valproate (Depakine Chrono)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional formulation of valproate (Depakine)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Valpromide (Depamide)
Number of subjects: 13
Study: 3372076

Group type: EXPERIMENTAL
Intervention: Magnesium aspartate hydrochloride (15 mmol per day for 6 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no magnesium supplementation)
Number of subjects: 20
Study: 29058821

Group type: EXPERIMENTAL
Intervention: Ledipasvir (120 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27227485

Group type: EXPERIMENTAL
Intervention: T1ρ and T2 relaxation time measurements in the nucleus pulposus (NP) and annulus fibrosus (AF) of lumbar intervertebral discs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated T1ρ and T2 metrics
Number of subjects: 0
Study: 25875447

Group type: EXPERIMENTAL
Intervention: 1.0 g dried ginger root powder (morning intake)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0 g dried ginger root powder (afternoon intake)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0 g dried ginger root powder (morning and afternoon intake)
Number of subjects: 0
Study: 23596262

Group type: COMPARATOR
Intervention: Single dose of praziquantel (40 mg/kg body weight)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Two doses of praziquantel (first dose followed by a second dose 2 weeks later)
Number of subjects: 395
Study: 20360498

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Water‐soluble lubricating gel alone (control)
Number of subjects: 72
Study: 18392897

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (RYGBP)
Number of subjects: 7